Lewis Asset Management LLC Sells 25,313 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Lewis Asset Management LLC cut its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 38.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,995 shares of the company's stock after selling 25,313 shares during the quarter. Lewis Asset Management LLC's holdings in Intellia Therapeutics were worth $478,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. State Street Corp lifted its holdings in shares of Intellia Therapeutics by 17.9% during the third quarter. State Street Corp now owns 5,143,534 shares of the company's stock worth $105,700,000 after buying an additional 780,754 shares in the last quarter. Hennion & Walsh Asset Management Inc. raised its stake in Intellia Therapeutics by 125.2% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 120,997 shares of the company's stock worth $1,411,000 after purchasing an additional 67,276 shares in the last quarter. Patient Square Capital LP bought a new stake in Intellia Therapeutics in the 3rd quarter valued at about $2,642,000. Dimensional Fund Advisors LP grew its position in shares of Intellia Therapeutics by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company's stock worth $29,648,000 after purchasing an additional 98,865 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Intellia Therapeutics by 4.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 827,545 shares of the company's stock worth $17,006,000 after purchasing an additional 37,714 shares during the period. Institutional investors and hedge funds own 88.77% of the company's stock.

Intellia Therapeutics Stock Performance

Shares of NTLA stock traded down $0.19 during mid-day trading on Friday, hitting $10.32. The company's stock had a trading volume of 2,161,568 shares, compared to its average volume of 3,145,072. Intellia Therapeutics, Inc. has a 52 week low of $9.25 and a 52 week high of $34.87. The company's fifty day simple moving average is $12.26 and its 200-day simple moving average is $17.62. The company has a market cap of $1.05 billion, a PE ratio of -1.90 and a beta of 1.83.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.37) by $0.03. The business had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. During the same quarter in the previous year, the company posted ($1.38) earnings per share. Intellia Therapeutics's quarterly revenue was down 24.1% on a year-over-year basis. On average, equities analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on NTLA. Chardan Capital boosted their price target on Intellia Therapeutics from $88.00 to $91.00 and gave the company a "buy" rating in a research note on Monday, November 18th. William Blair restated a "neutral" rating and issued a $14.00 price target on shares of Intellia Therapeutics in a research report on Monday, November 18th. BMO Capital Markets cut their price objective on shares of Intellia Therapeutics from $70.00 to $50.00 and set an "outperform" rating for the company in a research report on Friday, January 10th. Morgan Stanley lowered shares of Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and decreased their target price for the company from $56.00 to $11.00 in a report on Monday. Finally, Citigroup decreased their price objective on shares of Intellia Therapeutics from $25.00 to $19.00 and set a "neutral" rating on the stock in a research note on Friday, October 25th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $48.71.

Insider Activity

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the company's stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the transaction, the chief executive officer now owns 941,115 shares in the company, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders have sold 29,000 shares of company stock worth $352,551. Company insiders own 3.20% of the company's stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.